Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MB07133/m2/day · 1 trial · 1 indication
To determine the dose-limiting toxicities (DLT) of MB07133; To determine the maximum-tolerated continuous infusion dose (MTD) of MB07133
| Arm | Type | Description |
|---|---|---|
| MB07133 Dose Level 1 | EXPERIMENTAL | 7-day continuous infusion in 28-day cycles |
| MB07133 Dose Level 2 | EXPERIMENTAL | 7-day continuous infusion in 28-day cycles |
| MB07133 Dose Level 3 | EXPERIMENTAL | 7-day continuous infusion in 28-day cycles |
| MB07133 Dose Level 4 | EXPERIMENTAL | 7-day continuous infusion in 28-day cycles |
| MB07133 Dose Level 5 | EXPERIMENTAL | 7-day continuous infusion in 28-day cycles |
| Name | Type | Description |
|---|---|---|
| MB07133 300mg/m2/day | DRUG | 7-day continuous infusion in 28-day cycles |
| MB07133 600 mg/m2/day | DRUG | 7-day continuous infusion in 28-day cycles |
| MB07133 1200 mg/m2/day | DRUG | 7-day continuous infusion in 28-day cycles |
| MB07133 1800 mg/m2/day | DRUG | 7-day continuous infusion in 28-day cycles |
| MB07133 2400 mg/m2/day | DRUG | 7-day continuous infusion in 28-day cycles |
Inclusion Criteria: * Patients with a diagnosis of local unresectable HCC confirmed by histology using fine needle aspirate (FNA) or liver biopsy. "Local" is defined as disease either restricted to the liver or contiguous with the liver and no identifiable extrahepatic disease. * Patients with Chil...
MB07133/m2/day is an investigational small molecule being studied for the treatment of hepatocellular carcinoma, a type of liver cancer. It is administered as an intravenous infusion and is currently in Phase 1 clinical development for this indication.
MB07133/m2/day is being developed by Ligand Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol LGND. The drug is in Phase 1 clinical development for hepatocellular carcinoma.
MB07133/m2/day is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed to evaluate its safety and tolerability in patients with unresectable hepatocellular carcinoma.
MB07133/m2/day has been studied in one completed Phase 1 clinical trial, identified as NCT00073736. This trial evaluated the safety and tolerability of intravenous infusion of MB07133 in 28 patients with unresectable hepatocellular carcinoma, and was conducted in the United States, Hong Kong, and Taiwan.
MB07133/m2/day is a formulation or dosing specification of the drug MB07133. The clinical trial for this asset, NCT00073736, refers to the drug as MB07133, and the drug name MB07133/m2/day indicates the dose per square meter of body surface area per day.